EUVIMEDEUVIMED entdecken
Vergleichsstudie

Clinical Evaluation of [18F]AlF-NOTA-GL01 PET/CT in patients with solid tumors: a prospective comparison with [18F]FDG and an exploratory [18F]FAPI-42 subset

Xingyu Mu, Shengyuan Xu, Zihao Chen, Hoi Yee Chow, Lei Zhang, Jingze Li, Chenchen Jiang, Jiamin Jin, Xuechen Li, Feng Xue, Wei Fu

European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 8394-8409

DOI: 10.1007/s00259-026-08151-3 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 24.08.2026. Verfasst von Xingyu Mu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The First Affiliated Hospital, Guilin Medical University, Guilin, 541001, China. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Neoplasms, Fluorides. Die Arbeit nennt 50 Literaturangaben. Gefördert von: the Natural Science Foundation of Guangxi Zhuang Autonomous Region, Natural Science Foundation of Guangxi Zhuang Autonomous Region, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This prospective study evaluated the clinical performance of [18F]AlF-NOTA-GL01 PET/CT, examined the relationship between tracer uptake and tumor FAP expression, and performed head-to-head comparisons with [18F]FDG and [18F]FAPI-42 PET/CT in exploratory subset. METHODS: Between August 2025 and March 2026, 106 patients completed [18F]AlF-NOTA-GL01 PET/CT and paired-tracer PET/CT; 103 underwent paired [18F]FDG PET/CT and 3 underwent paired [18F]FAPI-42 PET/CT. Lesion SUVmax and tumor-to-background ratio (TBR) were compared on a lesion basis. In tumors with available histology, FAP expression was quantified by immunohistochemistry and correlated with lesion SUVmax. Patient- and lesion-based diagnostic performance was assessed against a composite reference standard. RESULTS: The final cohort comprised 106 patients (55 men, 51 women; mean age, 61.3 ± 9.0 years), including 102 malignant tumors and 4 benign lesions. Lesion [18F]AlF-NOTA-GL01 SUVmax correlated strongly with tumor FAP expression (r = 0.754, P < 0.001) and increased across low, intermediate, and high FAP-expression tumors. In patient-based analysis, [18F]AlF-NOTA-GL01 showed higher sensitivity than [18F]FDG (98.9% vs. 90.8%, P = 0.039), with comparable specificity (62.5% vs. 62.5%, P = 1.000). In lesion-based analysis, [18F]AlF-NOTA-GL01 outperformed [18F]FDG in sensitivity (96.4% vs. 71.3%, P < 0.001), specificity (50.6% vs. 24.7%, P = 0.003), and accuracy (90.5% vs. 65.3%, P < 0.001). In an exploratory subset, [18F]AlF-NOTA-GL01 showed lower normal-organ background and higher lesion-to-background ratios than [18F]FAPI-42. CONCLUSION: [18F]AlF-NOTA-GL01 uptake was associated with tumor FAP expression and demonstrated higher lesion-based sensitivity and accuracy than [18F]FDG in this single-center cohort, although specificity remained modest. These findings support further clinical development of [18F]AlF-NOTA-GL01 as a broadly applicable, scalable FAP-targeted PET agent.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyFluorodeoxyglucose F18NeoplasmsFluoridesHeterocyclic CompoundsHumansFemaleMaleMiddle AgedProspective StudiesAgedFibroblast Activation Protein AlphaAdultRadiopharmaceuticalsSerine EndopeptidasesEndopeptidasesAluminum Compounds

Stichwörter der Autor:innen

FAPIFibroblast activation proteinPET/CTSolid tumors[18F]AlF-NOTA-GL01[18F]FDG

Substanzen

Fluorodeoxyglucose F18Fibroblast Activation Protein AlphaFluoridesHeterocyclic CompoundsRadiopharmaceuticalsSerine Endopeptidasesaluminum fluorideEndopeptidasesAluminum Compounds

Autor:innen und Institutionen

  • Department of Nuclear Medicine, The First Affiliated Hospital, Guilin Medical University, Guilin, 541001, China.
  • Department of Oncology, The First Affiliated Hospital, Guilin Medical University, Guilin, 541001, China.
  • Key Laboratory Project of Guangdong Provincial Department of Education for Ordinary Universities and GDMPA Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Nanfa…
  • Serilink Biotechnology Company Limited, Hong Kong, 999077, China.
  • Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, Guangxi, 541199, China.
  • Department of Chemistry, State Key Laboratory of Synthetic Chemistry, The University of Hong Kong, Hong Kong, 999077, China. xuechenl@hku.hk.

Förderung

  • the Natural Science Foundation of Guangxi Zhuang Autonomous Region
  • Natural Science Foundation of Guangxi Zhuang Autonomous Region
  • National Natural Science Foundation of China
  • Innovative Research Group Project of the National Natural Science Foundation of China

Zitieren

APA

Mu, X., Xu, S., Chen, Z., Chow, H. Y., Zhang, L., Li, J., Jiang, C., Jin, J., Li, X., Xue, F., & Fu, W. (2026). Clinical Evaluation of [18F]AlF-NOTA-GL01 PET/CT in patients with solid tumors: a prospective comparison with [18F]FDG and an exploratory [18F]FAPI-42 subset. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 8394-8409. https://doi.org/10.1007/s00259-026-08151-3

Vancouver

Mu X, Xu S, Chen Z, Chow HY, Zhang L, Li J, et al. Clinical Evaluation of [18F]AlF-NOTA-GL01 PET/CT in patients with solid tumors: a prospective comparison with [18F]FDG and an exploratory [18F]FAPI-42 subset. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):8394-8409. doi:10.1007/s00259-026-08151-3

BibTeX
@article{Mu2026,
  author = {Mu, Xingyu and Xu, Shengyuan and Chen, Zihao and Chow, Hoi Yee and Zhang, Lei and Li, Jingze and Jiang, Chenchen and Jin, Jiamin and Li, Xuechen and Xue, Feng and Fu, Wei},
  title = {Clinical Evaluation of [18F]AlF-NOTA-GL01 PET/CT in patients with solid tumors: a prospective comparison with [18F]FDG and an exploratory [18F]FAPI-42 subset},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {13},
  pages = {8394--8409},
  doi = {10.1007/s00259-026-08151-3}
}
Kostenlos starten →